Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02601937
Title A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Epizyme, Inc.
Indications
Therapies
Age Groups: child | adult
Covered Countries USA | ITA | FRA | DEU | CAN


No variant requirements are available.